China: Legal Debriefs – The Revised Administrative Measures For Drug Registration (Draft For Comment)

Last Updated: 18 December 2017
Article by Helen Cheng and Jenson Li

On October 23, 2017, the China Food and Drug Administration ("CFDA") released the revised Administrative Measures for Drug Registration ("Draft for Comment") for public comment.

This Draft for Comment represents the implementation of the State Council's Opinions on Reforming the Review and Approval System for Drugs and Medical Devices (Guo Fa [2015] No. 44) published by the State Council on August 18, 2015 and the Opinions on Deepening the Reform of Review and Approval System for Drugs and Medical Devices to Encourage Innovation released by the General Office of State Council (Ting Zi [2017] No. 42) a few days ago. Aiming to address issues such as inadequate ability of drug innovation as well as lengthy review and approval procedure for clinical trial applications and marketing applications in China, it is also the summary and extension of a series of significant policies reforming the drug review and approval system since 2015. 

Fully Implement the Marketing Authorization Holder ("MAH") System

The MAH system, which adopts the management mode that separates drug marketing authorization from drug manufacturing authorization, is a common practice in the area of drug regulation in Europe, the United States, Japan and other countries and regions with advanced pharmaceutical markets. The document Guo Fa [2015] No. 44 proposed to launch a pilot drug MAH scheme. On June 6, 2016, the State Council released the Pilot Plan for the Drug Marketing Authorization Holder System ("Pilot Plan"), according to which ten provinces and municipalities including Beijing, Tianjin, Hebei and Shanghai began to implement the pilot scheme. The document Ting Zi [2017] No. 42 now proposes to summarize experience acquired from the pilot scheme and implement the drug MAH system throughout the country accordingly.

Under such mode, marketing authorization will be independent from manufacturing authorization, and drug marketing authorization holders can either manufacture by themselves or engage drug manufacturers to manufacture their drugs. By allowing research and development institutions to engage drug manufactures for manufacturing matters after obtaining drug approval numbers, this mode can create possibilities for research and development institutions to choose soft assets, and is beneficial to the encouragement of drug innovation, improvement of drug quality and prohibition of low-quality repetitive construction.

One thing to be noted is that drug marketing authorization applicants are defined as "institutions" in this Draft for Comment while they were defined as "research and development institutions" or "research personnel" in the Pilot Plan, and as "domestic entities" in the draft amendment released in 2016. By limiting applicants to "institutions", this Draft for Comment rules out the possibility for a natural person to be the applicant, which should have something to do with the heavy liabilities imposed by the Draft for Comment on drug marketing authorization holders. According to the Draft for Comment, not only will the applicant be responsible throughout the entire process of drug development, production and registration application, it should also render ongoing supervision and study over the drugs approved for marketing, perform lifecycle management of drugs and assume legal liabilities. These requirements are rather burdensome for ordinary research personnel, and are not easy to be fully implemented. 

Reform the Review and Approval System and Enhance the Efficiency of Approval

Clinical trials to be changed from "commencing after approval" to "commencing with implied approval"

One of the major measures to improve the efficiency of review and approval is to render "easier access" to clinical trial approval. In the past, clinical trials are permitted to start only upon receipt of clinical trial approval. But according to the Draft for Comment, clinical trials applications will be deemed to be approved if the CFDA does not raise any rejections or deficiency notices, in which case applicants can print out the approval documents by themselves and proceed with clinical trials; with respect to applicants of imported drugs, they can rely on the printed approval documents to attend to the customs clearance for the drugs to be used in the clinical trials. Changing the commencement of clinical trials into "commencement with implied approval" can impel the CFDA to optimize the drug review and approval procedure and increase its efficiency, in order to deliver its review conclusion within the prescribed time limit. As for the applicants, they will no longer need to wait for clinical trial approvals, but can go straight towards clinical trials upon the expiry of the prescribed time limit. 

On-site inspections to be changed from compulsory into where necessary

The current Administrative Measures for Drug Registration requires that during the process of drug registration, the CFDA should perform on-site inspections to clinical trials, and prior to granting marketing appTroval, the CFDA should perform on-site inspections on the manufacturing sites. However according to the Draft for Comment, regardless of whether it is for clinical trial applications or drug marketing applications, the CFDA can conduct on-site inspections only when it deems necessary; the only exception is that the CFDA should conduct on-site inspections on the manufacturing site of relevant samples of the drugs that are applied for marketing approval as specified in the applications. Since the time of on-site inspection itself is not calculated into the timeline of registration procedure, on-site inspections and sample tests will no longer be the prerequisites for the review and approval of drug registration in most cases, which can greatly save the time required for drug registration. 

The review of drugs, excipients and packaging materials to be changed from separate procedures into associated procedures

The Draft for Comment confirms the associated review of drugs, excipients and packaging materials, a system that has been implemented in the previous reform. In addition, it supplements this system with the associated review of active ingredients and drugs based on the document Ting Zi [2017] No. 42. Accordingly, active ingredients, pharmaceutical excipients and packaging materials will not go through marketing approval procedures individually but will become part of the review and approval of the marketing applications of corresponding preparations. Associated review not only helps to save review resources and administrative costs and shorten the timeline of review and approval, but also emphasizes the responsibilities of the pharmaceutical companies to conduct strict quality control towards their suppliers of active ingredients. 

Differentiate Categories of Changes and Implement Category Management

Information and contents related to the drugs may be changed either during clinical trials or after the drugs enter into the market. During the clinical trials, which is at the stage of research, it is quite common to change the prescriptions or dosage of the drugs based on the feedbacks. After a drug enters into the market, changes such as replacing the supplier of excipients or optimizing quality control system may also be necessary. Companies may encounter with obstacles on their way of drug research and development or drug optimization if the changing procedure is too complicated or if any kinds of change require approval, regardless of the degree of change, or even regardless of whether it has any impact on the drug safety and efficacy.

The Draft for Comment classifies the changes during clinical trials into ordinary changes and significant changes. Significant changes include changes in clinical study protocols that may affect the safety of the study subjects and changes that will apparently affect drug safety, efficacy, and quality evaluation. The applicants can make ordinary changes directly after analysis and assessment. For significant changes, the relevant applicant should submit an application for change to the CFDA, but the approval approach will be "implied approval if no rejection within the prescribed time limit", meaning the applicant can implement a significant change if it does not receive any rejections or deficiency notices from the CFDA within the prescribed time limit.  Such system can provide the applicants with more autonomy in making changes during clinical trials. Furthermore, the applicants can make ordinary changes during clinical trials in their own decision without any interruption to the then-current clinical trials, which can help the research and development to move forward smoothly.

With respect to post-marketing changes, the Draft for Comment proposes to classify them into three categories according to the degree of impact they could have on drug safety, efficacy and quality control, namely, minor changes, moderate changes and significant changes. Minor changes refer to those that could have slight impact or almost no impact on drug safety, efficacy and quality control, which can be made by the marketing approval holders themselves and filed for recordal with the CFDA in the meantime. Moderate changes refer to those that could have moderate impact on drug safety, efficacy and quality control, for which the marketing approval holders are required to submit a supplementary application, while the approval approach will be "implied approval if no rejection within the prescribed time limit". Finally, significant changes refer to those that could have apparent impact on drug safety, efficacy and quality control, and the marketing approval holder must obtain approval before their implementation. The Draft for Comment specifies the categories of some changes. For example, changes to the information on the drug package inserts should be managed as significant changes while changes to the name of the marketing approval holder which only adjust the wording should be managed as moderate changes. However, since "slight", "moderate" and "apparent" are all degree words, the specific categories of other changes will need to be determined according to the actual situation in practice. 

Emphasize Clinically Oriented Drug Innovation and Achieving Consistency between Generic Drugs and Originator's Drugs

The Draft for Comment encourages clinically oriented drug innovation. According to Article 90, innovative drugs should have clear clinical value, and improved new drugs should have apparent clinical advantages as compared to the original type. In order to enjoy convenience in bidding and other aspects, companies had long been focusing on superficial work such as simple changes to the dosage or increase in the specifications, which has lead to serious backlog in drug review and approval, and forced market exit among companies with true innovative spirits. On the contrary, encouraging clinically oriented drug innovation can prevent pseudo innovative drugs that re-enter the market right after simple changes or increases, improve the efficiency in utilizing resources for review and approval, and bring real technological innovation into the pharmaceutical industry.

With respect to the generic drugs, the Draft for Comment expressly provides that generic drugs should have quality and efficacy equivalent to those of the relevant originator's drugs or reference products. This requirement implements the Opinions on Conducting Consistency Evaluation of the Quality and Efficacy of Generic Drugs released by the State Council on March 5, 2016. China is a big market of generic drugs and is dominated by varieties of generic drugs. However, generic drugs are surrounded by issues including uneven quality, low standard of imitation and unclear efficacy of certain drugs. In the past, approved drugs were not mandatorily required to be evaluated as to their consistency with the originator's drugs in quality and efficacy, which accounts for the difference in efficacy between some generic drugs and the originator's drugs. The implementation of consistency requirement for generic drugs will raise the threshold in the industry of generic drugs and promote the market entry of generic drugs with high quality.

Other changes worth attention include the establishment of priority review and approval system, clinical data protection system, acceptance of overseas trial data into the marketing approval application process and centralization of the authority to acceptance registration applications from local counterparts to the CFDA, and specific implementing rules for some of these systems remain to be promulgated separately. The current Administrative Measures for Drug Registration has been effective for ten years and is no longer able to meet the needs of practice and developments to encourage drug innovation and improve drug quality. This revised draft is a subversive amendment to the current Administrative Measures for Drug Registration and upon its formal enactment, it will have profound influence on the drug research and development, as well as drug registration. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Toby Mak
CMS Cameron McKenna Nabarro Olswang LLP
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Toby Mak
CMS Cameron McKenna Nabarro Olswang LLP
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions